Crown Laboratories and Revance Therapeutics Announce Expiration of Tender Offer
Crown Laboratories, Inc. ("Crown") and Revance Therapeutics, Inc. (NASDAQ: RVNC) ("Revance"), today announced that the tender offer to purchase all of the issued and outstanding shares of common stock ...
Peptide Synthesis Market to Hit USD 1.41 Billion by 2029 with 11.7% CAGR | MarketsandMarkets™.
The Peptide Synthesis market valued at US$ 0.78 Billion in 2023, is forecasted to grow at a robust CAGR of 11.7%, reaching ...
Monopar's Incredible Journey From $5 To $50 In Less Than 5 Months
From the brink of Nasdaq delisting last year due to non-compliance with the minimum bid price rule, this clinical-stage biotechnology ...
CERo Therapeutics Announces $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules
The closing of the Offering is expected to occur on or about February 7, 2025, subject to the satisfaction of customary closing conditions. The gross proceeds from the Offering are expected to be ...